Sooma's patented stimulation electrodes
The company’s Sooma Comfort line of stimulation accessories delivers direct current from its Sooma tDCS neuromodulation device to specific brain regions.
soomamedical.comCrawled Nov 15, 2026
The company’s Sooma Comfort line of stimulation accessories delivers direct current from its Sooma tDCS neuromodulation device to specific brain regions.
The Sooma portal’s Outcomes page aggregates patient responses to treatment using questionnaires like PHQ-9, GAD-7, WHODAS 2.0, and NPRS for pain.
Sooma troubleshooting guide for patients and clinicians. Fix Bluetooth issues, errors, contact problems, and device faults step by step.
Version 1.2.11 of the software introduces fixes for the Patient Mobile Application and Clinician’s Web Portal, including initial password reset functionality.
Version 1.2.8 of the software updates the Patient Mobile Application and Clinician’s Web Portal with usability improvements and bug fixes.
Turku University Hospital uses Sooma tDCS devices in its Neuropsychiatry and Clinical Neurophysiology departments.
Sooma published a peer-reviewed study on its real-world data for treating Major Depressive Disorder (MDD) in the *Journal of Affective Disorders Reports*.
Estonia’s public healthcare system now reimburses tDCS treatments for psychiatric and neuropathic patients.
The World Health Organization estimates 5% of adults (280 million people) live with depression, a leading cause of global disability.
International guidelines now classify tDCS as Level A (definitely effective) for treating Major Depressive Disorder (MDD).
Medical device regulations can be complex, especially with rapid advancements in brain stimulation technology.
The latest news and updates on Sooma tDCS, neurostimulation treatment, and what’s happening at Sooma Medical.
Sooma meets the EU Medical Device Regulation (MDR) standards, earning certification from the Finnish notified body SGS.
Sooma received approval from Singapore’s Health Sciences Authority (HSA) to market its tDCS platform in Singapore.
Sooma Duo enables remote depression treatment with a medical device, treatment platform, and patient app.
The Hospital District of Southwest Finland (VSSHP) procured Sooma tDCS devices for 2020–2021, with an option to extend until 2024.
Sooma Medical develops the world’s most prescribed tDCS therapy.
Since 2013, Sooma Medical has collaborated with psychiatry and neurophysiology experts to develop non-drug treatments for depression and chronic pain.
Since 2013, Sooma Medical has worked with leading psychiatry and neurophysiology experts to create safe, non-pharmaceutical treatments for depression and chronic pain.
Sooma Medical is a Finnish health technology company pioneering brain stimulation therapies.
Sooma Medical is the company behind the world’s most prescribed tDCS therapy.
The first EU MDR-approved tDCS system: a safe, drug-free, non-invasive treatment for depression and chronic pain — in clinic or at home.
Sooma Oy complies with privacy laws to protect personal data, using it only as outlined in its Privacy Policy.
Sooma’s app collects only the personal data necessary for system functionality, with user consent.
Sooma Oy, based in Helsinki, provides a privacy policy outlining how personal data is used across its online services, with Tuomas Neuvonen as the data protection contact.
Sooma offers a 30-day money-back guarantee for webshop purchases.